Karyopharm Therapeutics (KPTI) Assets (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Assets came in at $108.4 million in Q4 2025, down 34.06% YoY from $164.4 million in Q4 2024, and up 12.66% on a QoQ basis from $96.2 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Assets (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Assets data on file, last reported at $108.4 million in Q4 2025.
- Quarterly Assets fell 34.06% year-over-year to $108.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $108.4 million (down 34.06% YoY) and the FY2025 annual result came in at $108.4 million, down 34.06% from the prior year.
- Assets climbed to $108.4 million in Q4 2025, from $96.2 million in the prior quarter.
- In the past five years, Assets ranged from a high of $358.2 million in Q4 2022 to a low of $96.2 million in Q3 2025.
- A 5-year average of $230.2 million and a median of $247.3 million in 2021 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets advanced 17.32% — and 2025, when it tumbled 50.99%.
- Tracing KPTI's Assets over 5 years: stood at $305.3 million in 2021, then grew by 17.32% to $358.2 million in 2022, then slumped by 32.87% to $240.4 million in 2023, then sank by 31.62% to $164.4 million in 2024, then plunged by 34.06% to $108.4 million in 2025.
- The last three Assets figures came in at $108.4 million (Q4 2025), $96.2 million (Q3 2025), and $104.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Karyopharm Therapeutics | 53.25 Mn | 53.25 Mn | 32.35 Mn | 111.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 111.32 Mn |
| Dec 31, 2025 | 108.42 Mn |
| Sep 30, 2025 | 96.23 Mn |
| Jun 30, 2025 | 104.88 Mn |
| Mar 31, 2025 | 127.71 Mn |
| Dec 31, 2024 | 164.42 Mn |
| Sep 30, 2024 | 189.48 Mn |
| Jun 30, 2024 | 213.98 Mn |
| Mar 31, 2024 | 204.46 Mn |
| Dec 31, 2023 | 240.44 Mn |
| Sep 30, 2023 | 269.96 Mn |
| Jun 30, 2023 | 297.83 Mn |
| Mar 31, 2023 | 325.80 Mn |
| Dec 31, 2022 | 358.17 Mn |
| Sep 30, 2022 | 231.24 Mn |
| Jun 30, 2022 | 256.48 Mn |
| Mar 31, 2022 | 294.03 Mn |
| Dec 31, 2021 | 305.31 Mn |
| Sep 30, 2021 | 254.09 Mn |
| Jun 30, 2021 | 286.57 Mn |